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Abstract
Background: It is not known whether the number of revascularizations modifies clinical 
outcomes in patients with ischemic cardiomyopathy (ICM) implanted with cardiac resynchro-
nization therapy defibrillator (CRT-D) vs. an implantable cardioverter-defibrillator (ICD)-only.
Methods: In Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchroniza-
tion Therapy (MADIT-CRT), we evaluated the effect of CRT-D vs. ICD-only on heart failure 
(HF) or death, on ventricular tachycardia (VT), ventricular fibrillation (VF) or death, and on 
reverse remodeling in 592 ICM patients with left bundle branch block, by the number of pre-
enrollment revascularizations (0, 1 or ≥ 2 revascularizations).
Results: There was a risk reduction of HF/death with CRT-D vs. ICD-only in all three 
sub-groups: ICM with no need for revascularization (HR 0.51 [0.26–1.02]; p = 0.055), ICM 
with 1 revascularization (HR 0.45 [0.30–0.70]; p < 0.001), and ICM with 2 or more revas-
cularizations (HR 0.37 [0.20–0.66]; p < 0.001). Similarly, there was a risk reduction of VT/ 
/VF/death with CRT-D vs. ICD-only in patients with no need for revascularization (HR 0.55 
[0.31–0.99]; p = 0.044); with 1 revascularization (HR 0.77 [0.51–1.18]; p = 0.23); or with 
≥ 2 revascularizations (HR 0.63 [0.34–1.17]; p = 0.14). There was a similar degree of left 
ventricular reverse remodeling in all three sub-groups (p > 0.05 for LVESV, LVEDV, and LAV 
percent change at 1-year follow-up).
Conclusions: In ICM patients, CRT-D is associated with a reduction in HF or death and 
VT/VF or death — irrespective of the frequency of pre-enrollment revascularization procedures 
— and is accompanied by a similar degree of beneficial left ventricular reverse remodeling. 
(Cardiol J 2016; 23, 4: 437–445)
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Introduction
Cardiac resynchronization therapy (CRT) has 
been shown to reduce heart failure (HF) hospi-
talization and mortality across the spectrum of 
patients with mild to severe drug-refractory HF, 
severely depressed left ventricular ejection frac-
tion (LVEF), and a wide QRS [1–6].
In the Multicenter Automatic Defibrillator 
Implantation Trial-Cardiac Resynchronization 
Therapy (MADIT-CRT), patients with ischemic 
cardiomyopathy (ICM) and non-ischemic cardio-
myopathy (NICM) patients had similar reduction 
in HF events or death with an implanted cardiac re-
synchronization therapy with defibrillator (CRT-D) 
vs. an implantable cardioverter-defibrillator (ICD)-
-only [7]. However, response to CRT-D in ICM pa-
tients is not uniform and therefore, better stratifi-
cation of CRT-D benefit is warranted in this cohort.
Prior studies suggested that the extent of scar 
among ICM patients predicts subsequent outcomes 
after CRT-D implantation [8–10]. However, scar 
burden is challenging to measure and quantify to 
this day. We hypothesized that a simple clinical 
parameter, the number of prior revascularization 
procedures might serve as a surrogate marker for 
the extent of myocardial scar. However, it is cur-
rently unknown whether CRT-D benefit might be 
stratified by the number of prior revascularization 
procedures among ICM patients.
Therefore, in this study, we aimed to assess 
clinical and echocardiographic response to CRT-D 
vs. an ICD-only in ischemic cardiomyopathy pa-
tients with left bundle branch block (LBBB) by 
the number of pre-enrollment revascularizations, 
enrolled in MADIT-CRT. We hypothesized that 
there will be a certain threshold of pre-enrollment 
revascularization procedure frequency, above 
which CRT-D vs. an ICD alone will no longer be 
clinically effective to improve outcomes.
Methods
Study population
The design, protocol and results of the MA-
DIT-CRT study were published previously [11, 
12]. Briefly, 1,820 patients with ICM (New York 
Heart Association [NYHA] functional class I or II) 
or NICM (NYHA functional class II only), LVEF 
of less than 30% and a prolonged QRS duration 
> 130 ms were randomized in a 3:2 ratio to receive 
CRT-D or ICD therapy. All eligible patients met 
the guideline criteria for ICD [13]. Patients were 
excluded with certain clinical characteristics, as 
described previously [11]. One hundred and ten 
hospital centers from North America and Europe 
participated in this international multicenter trial. 
The present study sample comprised 592 (of the 
1,820) patients with ICM and LBBB enrolled in 
MADIT-CRT (33%) patients of whom 353 (60%) 
were randomized to CRT-D therapy. We also report 
outcomes on 434 patients with ICM and non-LBBB. 
The study was in compliance with the Declaration 
of Helsinki and all enrolling sites had the protocol 
being approved by the local Institutional Review 
Board. All patients provided informed consent 
before the enrollment.
Data acquisition and patient follow-up
The MADIT-CRT trial was carried out from 
December 22, 2004 through June 22, 2009. After 
publication of the primary results, post-trial follow-
-up was conducted for all 1,691 surviving study 
participants until September 10, 2010 (phase 1 of 
the extended follow-up).
Echocardiography methods
Echocardiography recordings were analyzed 
off-line at the Brigham and Women’s Hospital, 
Boston, Massachusetts as an independent echocar-
diography core laboratory [11]. Echocardiography 
investigators analyzing the images were blinded 
to clinical characteristics, treatment assignment, 
or outcomes. Left ventricular (LV) volumes were 
measured by Simpson’s disk method in the apical 
4- and 2-chamber views and LVEF was calculated 
according to the American Society of Echocardi-
ography protocols [14].
Definitions and endpoints
We restricted our analysis to patients with 
baseline LBBB morphology as previous studies 
illustrated that only LBBB patients demonstrated 
a significant reduction in the combined endpoint 
of HF or death with CRT-D vs. ICD-only, while 
patients with non-LBBB morphology demonstrated 
a trend towards higher mortality with CRT [15]. 
Revascularization was defined as any percuta-
neous coronary intervention (PCI) or coronary 
artery bypass grafting (CABG) performed prior 
to enrollment; patients without revascularization 
were deemed to have ICM if they have had any 
myocardial infarctions prior to enrollment or were 
classified ischemic by the enrolling physician.
The primary endpoint of the current study 
was the first occurrence of a HF episode or death 
from any cause (HF/death); the secondary endpoint 
was the first occurrence of ventricular tachycardia 
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(VT), ventricular fibrillation (VF), or death from 
any cause (VT/VF/death).
The diagnosis of HF was made if patients 
were exhibiting signs and symptoms consistent 
with congestive HF that resulted in intravenous 
decongestive treatment in an outpatient setting 
or augmented decongestive therapy with oral or 
parenteral medications during an in-hospital stay.
Arrhythmia episodes included VT or VF with 
appropriate therapy of anti-tachycardia pacing or 
shock. Definition of VT was set from a rate of 180 
bpm (recommended programming) up to 250 bpm, 
ventricular (V) rate ≥ atrial (A) rate if 1:1 A:V, 
V-V changes drive A-A changes. VF was defined 
as ventricular rate > 250 bpm with disorganized 
ventricular electrocardiograms.
Adjudication of the endpoints was carried 
out by an independent mortality committee 
and a heart-failure committee unaware of treat-
ment assignments and clinical parameters, ac-
cording to pre-specified criteria, as described 
previously [11].
Statistical analysis
All analyses in the present study were carried 
out on an intention-to-treat basis (i.e., according 
to the original treatment assignment regardless 
of in-trial or post-trial crossovers). Variables were 
expressed as means ± standard deviation, and 
categorical data were summarized as frequencies 
and percentages. The clinical characteristics of the 
patients at baseline were compared between the 
subgroups, with the use of the Kruskal-Wallis test 
for continuous variables and the c2 test or Fisher’s 
exact test for dichotomous variables.
The Kaplan-Meier method was used to deter-
mine cumulative probabilities of death from any 
cause, nonfatal heart-failure events, and ventricular 
tachyarrhythmias, according to treatment group, 
ischemic status, and the number of revasculariza-
tions. Between-group comparisons of cumulative 
event rates were calculated by means of the log-
rank test.
Multivariate Cox proportional-hazards regres-
sion analyses were used to evaluate the effect of 
CRT-D on the following endpoints: 1) combined end-
point of death from any cause and a nonfatal heart-
failure event; 2) combined endpoint of ventricular 
tachyarrhythmia or death from any cause. The Cox 
model was adjusted for relevant clinical covariates 
with the use of best-subset regression modeling. 
The benefit of CRT-D therapy as compared with 
ICD therapy alone among patients with LBBB and 
those without LBBB was assessed by including 
a term for interaction between treatment and pres-
ence or absence of LBBB.
All statistical tests were 2-sided and a p-value 
of < 0.05 was considered statistically significant. 
The p values for interaction are reported. Analyses 
were carried out with the use of SAS software, 
version 9.4 (SAS Institute, Cary, NC).
Results
Study population
The median follow-up of the enrolled patients 
during the trial was 2.4 years (interquartile range, 
1.8–3.2). Clinical characteristics of the 592 pa-
tients included in this study were similar in the 
ICD-only and CRT-D groups. However, as the 
amount of revascularizations increased among 
the studied sub-groups, there was an increasing 
amount of patients of white race and ischemic 
NYHA I, while patients were less likely to be 
female (Table 1).
Among the 299 ischemic patients that had 
undergone 1 revascularization, 163 had a prior 
CABG and 136 had prior PCI. For the 152 ischemic 
patients with multiple revascularizations, 117 had 
a history of a prior CABG, while 135 had a history 
for a prior PCI. These patients had a range of re-
vascularization procedures from 2 to a maximum 
of 9 revascularizations.
CRT-D effect in ICM patients with LBBBs 
based on the number of revascularizations
In ICM patients with no revascularizations, 
univariate cumulative probabilities for HF or death 
illustrate a statistically significant benefit for CRT-D 
therapy (p = 0.030; Fig. 1A), and a trend for benefit 
for VT/VF/death (p = 0.051; Fig. 2A) at 4 years. 
In the multivariate analysis adjusted for current 
smoking, female sex, left ventricular end-systolic 
volume (LVESV), and history of prior ventricular 
arrhythmias, there was a trend toward CRT-D ben-
efit for the primary outcome of HF or death (HR 
0.51, 0.26–1.02, p = 0.055; Table 2), and a statisti-
cally significant benefit of CRT-D vs. an ICD alone 
for VT/VF/death (HR 0.55, 0.31–0.99, p = 0.044; 
Table 3) in LBBB patients with no pre-enrollment 
revascularizations.
In ICM patients with 1 revascularization, 
univariate estimates for HF or death showed a sta-
tistically significant benefit for CRT-D therapy vs. 
ICD-only (p < 0.001; Fig. 1B) and a trend towards 
CRT-D vs. ICD for VT/VF/death at 4 years (p = 
= 0.153; Fig. 2B). In the multivariate analysis, 
there was a significant benefit of CRT-D for HF/ 
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/death (HR 0.45, 0.30–0.70, p < 0.001; Table 2) with 
a trend towards benefit of CRT-D vs. ICD alone 
for VT/VF/death (HR 0.77, 0.51–1.18, p = 0.23; 
Table 3).
Among ICM patients with 2 or more revas-
cularizations, Kaplan-Meier analyses for HF 
or death suggested a statistically significant 
benefit for CRT-D vs. ICD-only (p = 0.003; 
Fig. 1C). Furthermore, there was a lower al-
beit non-significant cumulative probability 
of VT/VF/death with CRT-D vs. ICD alone 
during the follow-up (p = 0.236; Fig. 2C). 
In the multivariate analysis, the significant benefit 
of CRT-D vs. an ICD to reduce HF or death was 
confirmed (HR 0.45, 0.30–0.66, p < 0.001; Table 2) 
and there was a trend towards a significant reduc-
tion in VT/VF/death with CRT-D vs. an ICD-only 
(HR 0.63, 0.34–1.17, p = 0.14; Table 3).
Echocardiographic reverse remodeling  
to CRT-D by the number  
of revascularization procedures
In patients randomized to CRT-D therapy, 
echocardiographic data at 1 year of follow-up illus-
trated a similar degree of reverse remodeling with 
respect to LV end-diastolic volume percent change 
(p = 0.66), LVESV percent change (p = 0.61), 
and left atrial volume percent change (p = 0.30) 
between the various groups of revascularization 
(Fig. 3).
Table 1. Baseline characteristics of the study population by the number of pre-enrollment  
revascularization procedures.
No  
revascularization  
(n = 141)
One prior  
revascularization  
(n = 299)
Two or more prior  
revascularization  
(n = 152)
P
Prior CABG 0 (0%) 163 (55%) 117 (77%) < 0.001*
Prior non-CABG (PCI) 0 (0%) 136 (45%) 135 (89%) < 0.001*
Age at enrollment [years] 67.1 ± 9.0 68.1 ± 9.1 69.3 ± 8.1 0.16
Female 30 (21%) 51 (17%) 15 (10%) 0.026*
White race 125 (89%) 282 (94%) 146 (97%) 0.018*
CRT-D treatment 86 (61%) 170 (57%) 97 (64%) 0.34
Diabetes 43 (30%) 112 (37%) 66 (44%) 0.07
Smoking 19 (14%) 30 (10%) 13 (9%) 0.32
Heart rate 67.5 ± 9.6 67.9 ± 11.5 66.1 ± 9.7 0.36
Systolic blood pressure 124.0 ± 17.8 122.7 ± 17.7 124.6 ± 17.3 0.50
Creatinine [mg/dL] 1.20 ± 0.35 1.20 ± 0.32 1.22 ± 0.35 0.88
Prior atrial arrhythmia 14 (10%) 51 (17%) 25 (17%) 0.13
Prior ventricular  
arrhythmia
14 (10%) 22 (7%) 15 (10%) 0.54
ACEI or ARB 137 (97%) 285 (95%) 141 (93%) 0.21
Aldosterone antagonists 41 (29%) 93 (31%) 37 (24%) 0.33
Amiodarone 6 (4%) 35 (12%) 15 (10%) 0.044*
Beta-blockers 132 (94%) 272 (91%) 145 (95%) 0.21
Diuretics 100 (71%) 212 (71%) 106 (70%) 0.96
QRS [ms] 160.3 ± 17.9 160.9 ± 19.5 159.0 ± 17.0 0.84
LVEF [%] 29.0 ± 3.0 28.6 ± 3.2 28.5 ± 3.7 0.35
LVEDV indexed by BSA 123.7 ± 27.5 123.5 ± 26.3 122.1 ± 27.6 0.55
LVESV indexed by BSA 88.2 ± 22.3 88.5 ± 21.0 87.9 ± 23.2 0.61
LAV indexed by BSA 45.8 ± 9.6 47.2 ± 10.1 48.3 ± 11.0 0.10
*Statistical significance; Continuous variables are shown as mean ± standard deviation. Categorical variables are shown as numbers (%); 
CABG — coronary artery bypass graft; PCI — percutaneous coronary intervention; CRT-D — cardiac resynchronization therapy with defibrilla-
tor; ACEI — angiotensin converting enzyme inhibitor; ARB — angiotensin receptor blocker; LVEF — left ventricular ejection fraction; LVEDV — 
left ventricular end-diastolic volume; LVESV — left ventricular end-systolic volume; LAV — left atrial volume; BSA — body surface area
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Figure 1. Kaplan-Meier curves of the cumulative probability of heart failure (HF) or death in patients with left bundle 
branch block. Kaplan-Meier curves illustrate a statistically significant benefit of cardiac resynchronization therapy with 
defibrillator (CRT-D) vs. implantable cardioverter-defibrillator (ICD)-only for patients with no revascularization (A), one 
revascularization (B), and two or more revascularizations (C).
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Figure 2. Kaplan-Meier curves of the cumulative probability of ventricular tachycardia/ventricular fibrillation (VT/VF) 
or death in patients with left bundle branch block. Kaplan-Meier curves illustrate a trend towards risk reduction with 
cardiac resynchronization therapy with defibrillator (CRT-D) vs. implantable cardioverter-defibrillator (ICD)-only in 
patients with no revascularization (A), one revascularization (B), and two or more revascularizations (C).
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Table 2. Multivariate analysis for CRT-D vs. ICD 
benefit for the primary outcome (heart failure/ 
/death) by the number of pre-enrollment revas-
cularization procedures.
Endpoint HR* CI P†
CRT-D vs. ICD in  
patients with no  
revascularization 
0.51 0.26–1.02 0.055
CRT-D vs. ICD in  
patients with 1  
revascularization 
0.45 0.30–0.70 < 0.001
CRT-D vs. ICD in  
patients with ≥ 2  
revascularizations 
0.37 0.20–0.66 < 0.001
†All p values for interaction for revascularization subgroups and 
treatment > 0.05; *Hazard ratio (HR) comparing CRT-D to ICD with  
models adjusted for current smoking, female sex, left ventricular 
end-systolic volume, and history of ventricular arrhythmias; CRT-D — 
cardiac resynchronization therapy with defibrillator; ICD — implant-
able cardioverter-defibrillator; CI — confidence interval
Outcomes in non-LBBB patients by the 
number of revascularization procedures
In patients with non-LBBB electrocardio-
graphy morphology at baseline, there were no 
statistically significant reductions in HF or death, 
or VT/VF or death by the number of pre-enrollment 
revascularization procedures (Table 4).
Discussion
The major finding of the present study is that 
among ICM patients with LBBB morphology, CRT-D 
was associated with a significant risk reduction of 
HF events or death compared to an ICD-only, irre-
spective of the frequency of pre-enrollment revas-
cularization procedures. However, there was a less 
pronounced benefit of CRT-D to reduce ventricular 
tachyarrhythmias or death that was seen among all 
three sub-groups compared to an ICD-only, possibly 
due to a higher potential for arrhythmogenesis in 
patients with any prior revascularization.
In the original MADIT-CRT study, subgroup 
analyses suggested that both patients with ICM and 
NICM derive similar benefit from implantation of 
a CRT-D with reduction of HF or death compared 
to an ICD alone [12]. However, after the publication 
of the primary report [12], additional  analyses il-
lustrated more pronounced LV reverse remodeling 
to CRT-D in patients with NICM patients compared 
to the ICM patients [7].
Differences in outcomes to CRT between 
patients with ICM or NICM are well established. 
While prior studies focused on differential response 
to CRT by the presence of ICM, in this analysis, 
we aimed to further subdivide ICM patients by the 
number of prior revascularization procedures as 
a proxy for the burden of nonviable myocardium to 
stratify the benefit to CRT-D.
Why did we choose prior revascularization pro-
cedures as the focus of our study? It is conceivable 
that a significant modifier of clinical outcomes in 
patients with ICM is the burden of nonviable myo-
cardium related to prior coronary events. However, 
measuring scar burden is currently a challenging 
task. There have been prior studies assessing 
outcomes to CRT-D by scar burden measured by 
strain echocardiography imaging, positron emis-
Table 3. Multivariate analysis for CRT-D vs. ICD 
benefit for ventricular tachycardia/ventricular fi-
brillation/death by the number of pre-enrollment 
revascularization procedures.
Endpoint HR* CI P†
CRT-D vs. ICD in  
patients with no  
revascularization 
0.55 0.31–0.99 0.044
CRT-D vs. ICD in  
patients with 1  
revascularization 
0.77 0.51–1.18 0.23
CRT-D vs. ICD in  
patients with ≥ 2  
revascularizations 
0.63 0.34–1.17 0.14
†All p values for interaction for revascularization subgroups and 
treatment > 0.05; *Hazard ratio (HR) comparing CRT-D to ICD with  
models adjusted for current smoking, female sex, left ventricular 
end-systolic volume, and history of ventricular arrhythmias;  
CRT-D — cardiac resynchronization therapy with defibrillator;  
ICD — implantable cardioverter-defibrillator; CI — confidence  
interval
Table 4. Multivariate analysis for heart failure 
(HF)/death and ventricular tachycardia/ventricu-
lar fibrillation or death (VT/VF/death) by the 
number of pre-enrollment revascularization pro-
cedures in non-left bundle branch block patients.
Endpoint HR* CI P†
HF/death      
No revascularization 0.77 0.29–2.08 0.602
1 revascularization 1.04 0.60–1.81 0.894
≥ 2 revascularizations 0.96 0.51–1.77 0.885
VT/VF/death
No revascularization 0.90 0.42–1.93 0.79
1 revascularization 1.43 0.91–2.25 0.12
≥ 2 revascularizations 0.75 0.43–1.32 0.32
†All p values for interaction for revascularization subgroups and 
treatment > 0.05; *Models adjusted for current smoking, female 
sex, left ventricular end-diastolic volume, and history of ventricular 
arrhythmias; HR — hazard ratio; CI — confidence interval
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sion tomography studies or magnetic resonance 
imaging, however, most of these methods have not 
been validated, require special equipment with extra 
time and costs for recording the images, and take 
a long time to analyze [16, 17]. Our study is unique 
in regarding the use of a simple clinical parameter, 
the number of prior revascularization procedures, 
as a surrogate marker for the burden of nonviable 
myocardium. Interestingly, the response to CRT-D 
for reduction in HF/death and VT/VF/death was not 
compromised with an increasing number of revas-
cularization procedures in ICM patients.
The potential explanation to our findings is that 
with increasing number of revascularization proce-
dures, patients are closer to “complete revasculari-
zation” and have less nonviable myocardium; thus, 
these patients derive a similar benefit with CRT-D for 
both VT/VF, HF, and death. An alternative explanation 
is that patients that did not undergo revascularization 
had an established myocardial infarction with a sub-
sequent larger scar burden; therefore, these patients 
are at higher risk for ventricular tachyarrhythmias 
and the CRT-D effect is more pronounced. This was 
illustrated in a study by Barsheshet et al. [18] in 
which patients without prior revascularization had 
a significantly higher risk of VT/VF/death compared 
to those with prior revascularizations.
Figure 3. Echocardiographic reverse remodeling to cardiac resynchronization therapy with defibrillator (CRT-D) by 
prior revascularization procedures. The effect of pre-enrollment revascularizations on CRT-D is independent from 
echocardiographic reverse remodeling as studied from baseline to 1-year of follow-up. All three groups demonstrated 
echocardiographic reverse remodeling with 25% reduction in left ventricular end-systolic volume (LVESV), 15% re-
duction in left ventricular end-diastolic volume (LVEDV), and 20% reduction in left atrial volume (LAV).
In a prior MADIT-CRT sub-study by Barshesh-
et et al. [19], high echocardiographic reverse re-
modeling — defined as greater than 25% reduction 
in LVESV — was associated with a significant re-
duction in the risk of ventricular tachyarrhythmias 
compared to an ICD-only. Similarly, in our study, 
each subgroup demonstrated both echocardio-
graphic reverse remodeling and a benefit of CRT-D 
to reduce ventricular tachyarrhythmias compared 
to ICD-only.
Our findings have important clinical implica-
tions. Clinicians can find evidence that patients 
with ICM and any number of pre-enrollment revas-
cularizations can benefit from CRT-D with respect 
to HF events, tachyarrhythmias, and death.
Limitations of the study
There are several limitations of the present 
study. First, this is a post-hoc analysis, the study 
groups were not equal in size and we had a rela-
tively small number of events leading to a limited 
statistical power. All interaction p-values for re-
vascularization subgroups and treatment were 
> 0.05. Our findings can only be hypothesis gen-
erating and further testing is required. Second, we 
used a number of revascularizations as a proxy for 
nonviable myocardium, as reported by the enrolling 
444 www.cardiologyjournal.org
Cardiology Journal 2016, Vol. 23, No. 4
physicians. However, the source data for this infor-
mation was verified at the enrolling sites to ensure 
that this information is reliable. Finally, without 
complete catheterization data there is an unknown 
extent and vascular distribution of prior ischemic 
events in this cohort however, such data are not 
available from prior CRT studies either. A larger, 
prospective study to assess CRT-D benefit with 
detailed information on prior myocardial events, 
and myocardial scar burden might be warranted.
Conclusions
Our sub-study from MADIT-CRT shows that 
in ICM patients with LBBB, CRT-D is associated 
with a significant reduction HF events or death 
and VT/VF/death, irrespective of the number of 
pre-enrollment revascularization. Furthermore, 
the benefit of CRT-D to reduce HF, ventricular 
tachyarrhythmias or death is accompanied with LV 
reverse remodeling.
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